Genetics, Health Care and Public Policy: An Introduction to Public Health Genetics
, by Alison Stewart , Philippa Brice , Hilary Burton , Paul Pharoah , Simon Sanderson , Ron Zimmern- ISBN: 9780521529075 | 0521529077
- Cover: Paperback
- Copyright: 6/11/2007
Foreword | p. xiii |
Acknowledgements | p. xiv |
Introduction | p. 1 |
The definition of public health genetics | p. 1 |
Genetic and environmental factors as determinants of health | p. 3 |
Genetic disease, complex disease and the combined effects of genetic and environmental factors | p. 6 |
The emergence and development of public health genetics | p. 9 |
Advances in epidemiology and its application to public health | p. 9 |
The rise of genetic epidemiology | p. 9 |
The growth of genetic science | p. 10 |
The impetus for public health genetics | p. 11 |
Community genetics | p. 13 |
Attitudes to public health genetics | p. 14 |
An international public health genetics network: the Bellagio initiative | p. 15 |
About this book | p. 18 |
Further reading and resources | p. 20 |
Principles of public health | p. 20 |
The emergence of public health genetics | p. 20 |
The human genome project and 'genomic medicine' | p. 20 |
Community genetics | p. 21 |
Current developments in public health genetics | p. 22 |
Genomics and global health | p. 22 |
Genetic science and technology | p. 23 |
Basic molecular genetics | p. 23 |
Genes and the genome | p. 25 |
Chromosomes | p. 25 |
The 'central dogma': DNA makes RNA makes protein | p. 26 |
Gene structure and expression in more detail | p. 27 |
The complexity of the genetic programme | p. 28 |
Genetic variation: mutation and polymorphism | p. 31 |
Cell division and the maintenance of the genome | p. 33 |
Meiosis and recombination: the formation of sex cells | p. 34 |
Inheritance patterns | p. 35 |
Genes and disease | p. 37 |
Mendelian ('single-gene') diseases | p. 38 |
Mitochondrial disorders | p. 39 |
Chromosomal disorders | p. 40 |
Diseases caused by disorders in epigenetic mechanisms | p. 41 |
Mendelian subsets of common diseases | p. 42 |
Multifactorial disease | p. 43 |
Cancer | p. 44 |
Some complexities of the relationship between genes and disease | p. 46 |
Penetrance | p. 46 |
Inherited and new mutations | p. 46 |
Genetic heterogeneity | p. 47 |
Variable expressivity | p. 47 |
Genetic technology | p. 48 |
Cutting and joining pieces of DNA | p. 48 |
Separating pieces of DNA in a mixture | p. 48 |
Detecting specific sequences: hybridisation | p. 48 |
Fluorescent in situ hybridisation (FISH) | p. 49 |
DNA cloning and clone libraries | p. 50 |
The polymerase chain reaction | p. 51 |
DNA sequencing | p. 51 |
DNA microarrays | p. 53 |
Markers and maps | p. 53 |
The human genome project | p. 55 |
Mapping human genetic variation: SNPs and haplotypes | p. 56 |
The post-genome challenge | p. 57 |
Identifying genes and studying gene function | p. 57 |
Proteomics | p. 57 |
Comparative genomics | p. 59 |
Bioinformatics | p. 59 |
Systems biology | p. 60 |
Epidemiological and biomedical informatics | p. 60 |
Further reading and resources | p. 61 |
Basic genetics | p. 61 |
Genes and disease | p. 61 |
Genomics and the human genome project | p. 63 |
The post-genome challenge | p. 63 |
Fundamentals of genetic epidemiology | p. 65 |
An overview of classical epidemiology | p. 65 |
Causation and association | p. 65 |
Measuring the occurrence of illness | p. 67 |
Measuring associations in analytical epidemiology | p. 69 |
Cohort and case-control studies | p. 70 |
Interaction | p. 73 |
Genetic epidemiology and human disease | p. 74 |
Genetic variation and disease susceptibility | p. 74 |
Clustering in families and the familial relative risk | p. 75 |
Using heritability to assess genetic and environmental contributions | p. 76 |
Determining the genetic model of inheritance: segregation analysis | p. 79 |
Identifying specific genetic determinants related to disease susceptibility | p. 80 |
Linkage and linkage analysis | p. 80 |
Association analysis | p. 84 |
Evaluating the characteristics of disease-susceptibility genetic variants | p. 96 |
Identifying whether gene variants are pathogenic variants | p. 97 |
Estimating disease allele frequency | p. 97 |
Estimating penetrance | p. 98 |
Gene-gene interactions | p. 99 |
Gene-environment interactions | p. 100 |
Study designs for gene-environment interactions | p. 100 |
Gene-environment interactions and Mendelian randomisation | p. 101 |
Further reading and resources | p. 103 |
Classical epidemiology | p. 103 |
Genetic epidemiology | p. 103 |
Systematic review and meta-analysis | p. 105 |
Genetics in medicine | p. 106 |
Genetic testing | p. 106 |
Diagnostic genetic testing | p. 107 |
Carrier testing | p. 108 |
Predictive genetic testing | p. 108 |
Testing for genetic susceptibility | p. 109 |
Population screening | p. 110 |
Methods of genetic testing | p. 111 |
Cytogenetic testing | p. 112 |
DNA testing | p. 112 |
Techniques for finding mutations | p. 114 |
Evaluation of genetic tests | p. 121 |
Challenges for evaluating genetic tests | p. 121 |
Genetics and disease prevention | p. 123 |
Genotypic and phenotypic prevention | p. 123 |
Identifying individuals at high genetic risk: family tracing | p. 124 |
Susceptibility genetics | p. 125 |
Family history as a tool in prevention of common disease | p. 126 |
Ecogenetics | p. 127 |
Nutrigenetics and nutrigenomics | p. 129 |
Genetics and disease management | p. 130 |
Pharmacogenetics | p. 130 |
Molecular genetic profiling in diagnosis and disease management | p. 137 |
Gene therapy | p. 138 |
Stem cell therapy | p. 144 |
Genetics and infectious disease | p. 147 |
Further reading and resources | p. 151 |
Genetic testing and screening | p. 151 |
Genetics and disease prevention | p. 151 |
Genetics and disease management | p. 153 |
Genetics in health services | p. 156 |
Organisation of clinical genetics services in the UK | p. 156 |
The multidisciplinary clinical team | p. 157 |
The clinical genetics consultation | p. 158 |
Cancer genetics | p. 161 |
Cardiac genetics | p. 162 |
Neurogenetics | p. 163 |
Genetic registers | p. 163 |
Laboratory genetics services | p. 164 |
Some services closely associated with genetics centres | p. 167 |
Inherited metabolic disease | p. 167 |
Haemoglobinopathies | p. 168 |
Inherited bleeding disorders | p. 169 |
The role of voluntary organisations | p. 170 |
Commissioning of genetics services | p. 171 |
Population screening programmes for genetic conditions | p. 172 |
Antenatal Down syndrome screening | p. 173 |
Haemoglobinopathy screening | p. 174 |
Neonatal cystic fibrosis screening | p. 174 |
Neonatal screening for inborn errors of metabolism | p. 175 |
Population carrier screening in specific communities | p. 175 |
Genetics in mainstream medicine | p. 176 |
Genetics in other specialist services: the multidisciplinary approach | p. 176 |
Development of service models for cancer genetics | p. 177 |
National Service Frameworks | p. 178 |
Genetics in primary care | p. 179 |
The future of genetics in clinical services | p. 181 |
Further reading and resources | p. 182 |
Organisation and development of genetic services | p. 182 |
Voluntary organisations | p. 183 |
Commissioning of genetics services | p. 183 |
Population screening | p. 183 |
Genetics in mainstream medicine | p. 184 |
Ethical, legal and social implications of genetics | p. 186 |
Genetic determinism and reductionism | p. 186 |
Geneticisation | p. 188 |
The legacy of eugenics | p. 189 |
Genetics and reproductive choice | p. 191 |
Antenatal genetic testing and screening | p. 191 |
Limits to reproductive choice? | p. 192 |
Genetics and assisted reproduction | p. 194 |
Embryo research and embryonic stem cells | p. 195 |
Genetic information | p. 197 |
Genetic exceptionalism | p. 198 |
Genetic databases | p. 199 |
Genetic discrimination | p. 206 |
Genetic information and insurance | p. 206 |
Genetic information and employment | p. 208 |
Justice and the 'genetic underclass' | p. 210 |
Genetics and racial discrimination | p. 211 |
Ethical and legal aspects of clinical genetics | p. 213 |
Confidentiality versus the duty to warn | p. 213 |
The right not to know | p. 214 |
Consent to genetic testing | p. 215 |
Public perceptions of genetics | p. 218 |
Further reading and resources | p. 219 |
Genetic reductionism, geneticisation and eugenics | p. 220 |
Genetics and reproductive choice | p. 220 |
Embryo research and embryonic stem cells | p. 221 |
Genetic information | p. 221 |
Genetic discrimination | p. 222 |
Ethical and legal aspects of clinical genetics | p. 223 |
Public perceptions of genetics | p. 223 |
Policy implications | p. 225 |
How government policy for genetics is developed in the UK | p. 226 |
The advisory and regulatory system for genetics | p. 227 |
The international context for genetics policy | p. 229 |
Policy for key issues in genetics | p. 233 |
Genetics in reproductive decision-making | p. 233 |
Consent to genetic testing and analysis | p. 238 |
Privacy and confidentiality of genetic information | p. 240 |
Protection against unfair discrimination | p. 247 |
Pharmacogenetics | p. 256 |
Regulation of gene-based and cellular therapies | p. 259 |
Clinical trials and research governance | p. 264 |
General governance of clinical research | p. 265 |
Intellectual property and patents | p. 265 |
General policy issues | p. 269 |
The scientific and clinical research base | p. 269 |
Public health policy | p. 273 |
The role of the commercial sector | p. 274 |
Financial considerations and health economics | p. 276 |
Education and training | p. 278 |
The public | p. 280 |
Concluding remarks | p. 281 |
Further reading and resources | p. 282 |
Policy development for genetics in the UK | p. 282 |
The international context | p. 284 |
Genetics in reproductive decision-making | p. 284 |
Assisted reproduction | p. 284 |
Consent to genetic testing and analysis | p. 285 |
Protection of medical and genetic information | p. 285 |
Protection against unfair discrimination | p. 286 |
Regulation of genetic tests | p. 286 |
Pharmacogenetics: policy issues | p. 286 |
Advanced therapies | p. 287 |
Clinical trials and research governance | p. 288 |
Intellectual property and patents | p. 288 |
General policy issues | p. 288 |
Scientific and clinical research policy, and relationships between the public and private sectors | p. 288 |
Health economics | p. 289 |
Education and training | p. 289 |
Public involvement | p. 289 |
Challenges for public health genetics | p. 290 |
Further reading | p. 291 |
Books, reports and journal papers | p. 291 |
Websites and web pages | p. 316 |
Index | p. 323 |
Table of Contents provided by Ingram. All Rights Reserved. |
The New copy of this book will include any supplemental materials advertised. Please check the title of the book to determine if it should include any access cards, study guides, lab manuals, CDs, etc.
The Used, Rental and eBook copies of this book are not guaranteed to include any supplemental materials. Typically, only the book itself is included. This is true even if the title states it includes any access cards, study guides, lab manuals, CDs, etc.
Digital License
You are licensing a digital product for a set duration. Durations are set forth in the product description, with "Lifetime" typically meaning five (5) years of online access and permanent download to a supported device. All licenses are non-transferable.
More details can be found here.